Summarized by Masters of Longevity from Singularity Hub.
In vivo CAR T therapy for neurological autoimmune disease — a concise preview of a small clinical trial report exploring safety, feasibility, and early clinical signals.
Key Takeaways
- A single intravenous delivery of a CAR-encoding viral vector was used to reprogram T cells inside the body of trial participants.
- In 16 patients with neurological autoimmune disorders, symptoms and molecular markers improved for more than six months without new nerve sheath damage.
- The trial reported few severe adverse events but lacked a control group and requires larger controlled studies to confirm durability and safety.
